Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
ABCD ScoreAdjusted Body WeightBody Mass IndexDiaRem ScoreIdeal Weight & Excess Weight Loss
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Recent Journal Updates

JAMAJun 9, 2026
New Obesity Framework Ignites Debate

Clinical Context

We think this might be relevant to the clinical guidance for Body Mass Index (BMI).

DiabetologiaJun 9, 2026
Fetal growth is driven by a bimodal fetal beta cell response and reshaped by a ketogenic diet in a mouse model of maternal diabetes

Clinical Context

We think this might be relevant to the clinical guidance for Body Mass Index (BMI).

DiabetologiaJun 6, 2026
Time-restricted eating versus dietetic guidance on glycaemic outcomes in adults at risk of type 2 diabetes: a non-inferiority randomised clinical trial

Clinical Context

We think this might be relevant to the clinical guidance for Body Mass Index (BMI).

Body Mass Index

Body Mass Index (WHO Classification): Validated screening tool for weight categories and obesity assessment. In bariatric surgery, BMI ≥40 or ≥35 with comorbidities guides surgical candidacy. Updated 2024 guidelines recommend evaluation for patients ≥35 with obesity-related comorbidities like type 2 diabetes, hypertension, sleep apnea, or GERD.

cm
kg
Underweight0–18.5
Normal Weight18.5–25
Overweight25–30
Obesity Class I30–35
Obesity Class II35–40
Obesity Class III (Morbid)≥ 40

Awaiting Input

WHO classification for adults

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Primary Clinical Uses

Population-level metabolic screening and surveillance
Bariatric surgery candidacy (BMI ≥40 or ≥35 with comorbidity)
Eligibility screening for GLP-1 receptor agonists (semaglutide/liraglutide)
Monitoring progress in structured weight management programmes
Risk stratification for T2DM, hypertension, sleep apnoea, and CVD

When NOT to Use Alone

AMA 2023 policy explicitly recommends against using BMI as the sole criterion for clinical decision-making, particularly for bariatric surgery eligibility or pharmacotherapy access.

Last Comprehensive Review: 2026